The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMW 2021 | Improving accessibility and affordability of myeloma therapies
Saad Usmani, MD, MBBS, MBA, of the Levine Cancer Institute/Carolinas HealthCare System, Charlotte, NC, talks on the accessibility and affordability of optimal therapies for patients with multiple myeloma. In particular, Dr Usmani comments on the need for innovation and partnerships between academic institutions and pharmaceuticals companies to reduce the cost of care in myeloma. This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.
Disclosures
Saad Usmani, MD, MBBS, MBA, has received research funding from Amgen, Array Biopharma, BMS, Celgene, GSK, Janssen, Merck, Pharmacyclics, Sanofi, Seattle Genetics, SkylineDX, Takeda; has received consulting fees from Abbvie, Amgen, BMS, Celgene, GSK, Genentech/Roche, Janssen, Karyopharm, Merck, Oncopeptides, Sanofi, Seattle Genetics, SkylineDx, Takeda; and has received speaking fees from Celgene, Janssen, Sanofi, Takeda.
